Under the terms of this agreement, Dyax will identify therapeutic antibodies for two targets provided by Bayer Schering Pharma. Furthermore, these research activities may be expanded to allow Dyax to work on additional targets and/or allow Bayer Schering Pharma to exercise an option for an antibody library license.
Dyax will receive clinical milestone payments and royalties on net sales that may result from Bayer Schering Pharma’s development and commercialization of any antibodies discovered through the collaboration.
The agreement also provides Bayer Schering Pharma with sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’s technology. Financial terms were not disclosed.
“Dyax consistently generates new therapeutic antibody technology collaborations and has developed into one of the leaders in the industry for antibody drug discovery,” commented Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax.
“We are excited about the growing value of our Licensing and Funded Research Program, and look forward to building on its success in the future.”